<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    Amicus Therapeutics, Inc.

    Amicus Therapeutics, Inc.

    Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-centric biotechnology comp...

    Amicus Therapeutics (Nasdaq: FOLD) is a global,...

    Filing Type:    PU
    Cytokinetics, Incorporated

    Cytokinetics, Incorporated

    Cytokinetics is a late-stage biopharmaceutical company focused on discovering, dev...

    Cytokinetics is a late-stage biopharmaceutical ...

    Filing Type:    PU
    Masimo Corporation

    Masimo Corporation

    We are a global medical technology company that develops, manufactures, and market...

    We are a global medical technology company that...

    Filing Type:    PU
    AtriCure, Inc.

    AtriCure, Inc.

    As a leading provider of innovative technologies for the treatment of Atrial Fibri...

    As a leading provider of innovative technologie...

    Filing Type:    PU
    GlycoMimetics, Inc.

    GlycoMimetics, Inc.

    At GlycoMimetics, we are committed to helping to make a difference in the lives of...

    At GlycoMimetics, we are committed to helping t...

    Filing Type:    PU
    Aeolus Pharmaceuticals, Inc.

    Aeolus Pharmaceuticals, Inc.

    Aeolus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses o...

    Aeolus Pharmaceuticals, Inc. is a biopharmaceut...

    Amount Raised:    $18,500,000
    Fundraising Status:    VT
    Filing Type:    PU
    Vir Biotechnology, Inc.

    Vir Biotechnology, Inc.

    Vir integrates diverse innovations in science, technology, and medicine to transfo...

    Vir integrates diverse innovations in science, ...

    Filing Type:    PU
    NextCure, Inc.

    NextCure, Inc.

    NextCure is a clinical-stage biopharmaceutical company committed to discovering an...

    NextCure is a clinical-stage biopharmaceutical ...

    Filing Type:    PU
    Celsion Corporation

    Celsion Corporation

    Celsion Corporation is a fully integrated biopharmaceutical company focused on dev...

    Celsion Corporation is a fully integrated bioph...

    Filing Type:    PU
    Genprex, Inc.

    Genprex, Inc.

    Genprex Inc is a U.S.-based clinical-stage gene therapy company. It is engaged in ...

    Genprex Inc is a U.S.-based clinical-stage gene...

    Filing Type:    PU
    MorphoSys AG

    MorphoSys AG

    MorphoSys (FSE & NASDAQ: MOR) is a clinical-stage biopharmaceutical company dedica...

    MorphoSys (FSE & NASDAQ: MOR) is a clinical-sta...

    Filing Type:    PU
    Clovis Oncology, Inc.

    Clovis Oncology, Inc.

    Founded in 2009, Clovis Oncology (NASDAQ: CLVS) is a commercial stage biotechnolog...

    Founded in 2009, Clovis Oncology (NASDAQ: CLVS)...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.